Esperion Therape Stock Price, News & Analysis

Esperion (NASDAQ: ESPR) has granted 49,300 restricted stock units (RSUs) to 15 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to continued employment. The grants were made as employment inducements under NASDAQ Rule 5635(c)(4).

Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi).

Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with HLS Therapeutics for exclusive commercialization rights of NEXLETOL and NEXLIZET in Canada. The agreement includes an upfront payment, milestone payments up to $5 million, and tiered royalties on product sales. Esperion will supply the finished product at a profitable transfer price.

The partnership aims to address a significant market, as approximately 2.6 million Canadian adults live with diagnosed heart disease, which is the second leading cause of death in Canada. HLS will handle commercialization, reimbursement, and marketing responsibilities in Canada, while Esperion maintains product supply duties.

Esperion (NASDAQ: ESPR) reported Q1 2025 financial results with total revenue of $65.0M, down 53% Y/Y due to a one-time milestone in Q1 2024. Excluding this milestone, revenue grew 63% Y/Y. U.S. net product revenue increased 41% Y/Y to $34.9M. The company achieved significant milestones, including surpassing 1 million retail prescriptions and receiving Level 1a recommendations in the 2025 ACC/AHA Guidelines. Esperion expanded its development portfolio with ESP-1336 for Primary Sclerosing Cholangitis (PSC), targeting a >$1B market. The company reported a net loss of $40.5M compared to net income of $61.0M in Q1 2024. Cash position stood at $114.6M as of March 31, 2025. The company expanded its reimbursement team and improved formulary positioning across 361 formularies.

Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.

Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.

Esperion (NASDAQ: ESPR) announced new research for treating Primary Sclerosing Cholangitis (PSC), a rare liver disease, at their R&D Day 2025. The company unveiled lead candidates, including ESP-1336, which are novel allosteric inhibitors of ATP citrate lyase (ACLY) targeting hepatic inflammation and fibrosis.

The preclinical data shows promising results in reducing liver injury, inflammation, and fibrosis across multiple PSC-relevant models. The company's research utilized multi-omics and phenome-wide association studies to identify ACLY mechanisms linked to bile duct injury and PSC progression.

The market opportunity is estimated at over $1 billion annually, with approximately 76,000 diagnosed PSC patients across the U.S. and Europe as of 2024. The program may be eligible for Orphan Drug and Fast Track designations from the FDA.

Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.

Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.

The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.

Esperion (NASDAQ: ESPR) has announced an upcoming R&D Day scheduled for April 24, 2025, at 9:00 a.m. ET in New York City. The event will showcase the company's research developments in ATP citrate lyase (ACLY) biology and its therapeutic applications for various life-threatening conditions.

The presentation will focus on how ACLY inhibitors could treat rare and chronic liver and kidney diseases. Esperion plans to reveal a new indication and introduce their lead candidate's development pathway. The event will feature key opinion leaders including Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital.

A live webcast will be available with pre-registration required on Esperion's website Investor section, with replay available for approximately 90 days after the event. In-person attendance requires advanced registration.

Esperion (NASDAQ: ESPR) has announced significant changes to its Board of Directors. Robert E. Hoffman has been appointed as an independent director, effective immediately, and will serve as Chairperson of the Audit Committee starting May 29, 2025. Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board effective June 1, 2025.

Hoffman brings extensive experience in the biopharmaceutical sector, having served as President, CEO, interim CFO, and Chairperson at Kintara Therapeutics (2021-2024). His previous roles include senior positions at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals. He currently serves on the boards of TuHURA Biosciences and Fibrobiologics, and has been a board member for several public and private life sciences companies.

Esperion (NASDAQ: ESPR) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference scheduled for April 7, 2025, at 8:45 a.m. ET. The event will be accessible via webcast through Esperion's website, with replay available for approximately 90 days.

Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function for rational drug design. Esperion continues to expand globally through commercial execution, international partnerships, and pre-clinical pipeline development.